Earnings Summary

Adagio Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Adagio Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Adagio Therapeutics Inc’s net profit fell -160.12% since last year same period to $-100.67Mn in the Q1 2022. On a quarterly growth basis, Adagio Therapeutics Inc has generated 28.11% jump in its net profits since last 3-months.

Adagio Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Adagio Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Adagio Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.82 - a 20.39% jump from last quarter’s estimates.

Adagio Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.82.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adagio Therapeutics Inc’s return on assets (ROA) stands at -0.37.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adagio Therapeutics Inc’s return on equity (ROE) stands at -0.68.